Collplant biotechnologies announces european patent allowance secured for its collagen-based formulations usable as soft tissue fillers and implants

- further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - rehovot, israel , june 4, 2025 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhcollagen for tissue regeneration and medical aesthetics, today announced that the european patent and trademark office has allowed a patent application related to collplant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively. this newly allowed patent application pertains to collplant's injectable soft tissue fillers as well as its organ manufacturing technology related to its regenerative breast implant pipeline currently under development.
CLGN Ratings Summary
CLGN Quant Ranking